Announced details
Acute spinal cord injury; patients with severe cervical spinal cord injuries assessed as AIS Grade A 72 hours after injury
Trends in safety and efficacy were observed, but specific figures were Not disclosed.
The publication venue for a paper summarizing the results of the Phase III clinical trial conducted by the company
An international academic journal. Other details: Not disclosed.
Clinical trial protocol number: KP-100-ND004; DOI: 10.1177/08977151261467225
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Journal of Neurotrauma; Miyakoshi N et al. Spinal Cord 2021 Jun;59(6):626-634; Shingu Hikosuke (新宮彦助), "Prevention of Spinal Cord Injury"; Sakai Hiroaki (坂井宏旭), "Epidemiological Survey"
| Item | Details |
|---|---|
| Names of Products / Services Covered | KP-100IT (recombinant human HGF protein formulation) |
| Counterparty | Journal of Neurotrauma (publication) |
| Counterparty overview | An international academic journal. Other details: Not disclosed. |
| Relationship with the Company | The publication venue for a paper summarizing the results of the Phase III clinical trial conducted by the company |
| Applicable area | Acute spinal cord injury; patients with severe cervical spinal cord injuries assessed as AIS Grade A 72 hours after injury |
| Registration number and expiry date | Clinical trial protocol number: KP-100-ND004; DOI: 10.1177/08977151261467225 |
| Quantitative Effects | Trends in safety and efficacy were observed, but specific figures were Not disclosed. |
| Source | Journal of Neurotrauma; Miyakoshi N et al. Spinal Cord 2021 Jun;59(6):626-634; Shingu Hikosuke (新宮彦助), "Prevention of Spinal Cord Injury"; Sakai Hiroaki (坂井宏旭), "Epidemiological Survey" |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The results of the Phase III clinical trial were published in an international academic journal. The company stated that it will continue development with the aim of providing patients with a new treatment option.